Nīderlande - holandiešu - CBG-MEB (College ter Beoordeling van Geneesmiddelen)

temozolomide 20 mg/stuk - capsule, hard - ammonia (e 527) ; gelatine (e 441) ; ijzeroxide geel (e 172) ; ijzeroxide zwart (e 172) ; lactose 0-water ; natriumzetmeelglycolaat ; propyleenglycol (e 1520) ; schellak glaze, gedeeltelijk veresterd ; siliciumdioxide (e 551) ; stearinezuur (e 570) ; titaandioxide (e 171) ; wijnsteenzuur, (l (+) vorm) (e 334) ; zwarte inkt

Nīderlande - holandiešu - CBG-MEB (College ter Beoordeling van Geneesmiddelen)

temozolomide 250 mg/stuk - capsule, hard - ammonia (e 527) ; gelatine (e 441) ; ijzeroxide zwart (e 172) ; lactose 0-water ; natriumzetmeelglycolaat ; propyleenglycol (e 1520) ; schellak glaze, gedeeltelijk veresterd ; siliciumdioxide (e 551) ; stearinezuur (e 570) ; titaandioxide (e 171) ; wijnsteenzuur, (l (+) vorm) (e 334) ; zwarte inkt

Nīderlande - holandiešu - CBG-MEB (College ter Beoordeling van Geneesmiddelen)

temozolomide 5 mg/stuk - capsule, hard - ammonia (e 527) ; gelatine (e 441) ; ijzeroxide geel (e 172) ; ijzeroxide zwart (e 172) ; indigokarmijn (e 132) ; lactose 0-water ; natriumzetmeelglycolaat ; propyleenglycol (e 1520) ; schellak glaze, gedeeltelijk veresterd ; siliciumdioxide (e 551) ; stearinezuur (e 570) ; titaandioxide (e 171) ; wijnsteenzuur, (l (+) vorm) (e 334) ; zwarte inkt

Nīderlande - holandiešu - CBG-MEB (College ter Beoordeling van Geneesmiddelen)

demo sa pharmaceutical industry 21st km nat. rd. athens-lamia 14568 krioneri, attica (griekenland) - docetaxel 0-water 20 mg/ml - concentraat voor oplossing voor infusie - citroenzuur 0-water (e 330) ; ethanol 395 mg/ml ; polysorbaat 80 (e 433) ; stikstof (head space) (e 941), - docetaxel

Nīderlande - holandiešu - CBG-MEB (College ter Beoordeling van Geneesmiddelen)

krka d.d., novo mesto smarjeska cesta 6 8501 novo mesto (sloveniË) - docetaxel 0-water - concentraat voor oplossing voor infusie - citroenzuur 0-water (e 330) ; ethanol 395 mg/ml ; polysorbaat 80 (e 433) ; stikstof (head space) (e 941), - docetaxel

Nīderlande - holandiešu - CBG-MEB (College ter Beoordeling van Geneesmiddelen)

sandoz b.v. veluwezoom 22 1327 ah almere - vinorelbineditartraat 13,85 mg/ml samenstelling overeenkomend met ; vinorelbine 10 mg/ml - concentraat voor oplossing voor infusie - stikstof (head space) (e 941) ; water, gezuiverd, - vinorelbine

Nīderlande - holandiešu - CBG-MEB (College ter Beoordeling van Geneesmiddelen)

zentiva a.s. u. kabelovny 130 10237 prague (tsjechiË) - everolimus 10 mg/stuk - tablet - butylhydroxytolueen (e 321) ; crospovidon (e 1202) ; hypromellose, type 2910 (3 - 15 mpa.s) (e 464) ; lactose 0-water ; lactose 1-water ; magnesiumstearaat (e 470b) - everolimus

Nīderlande - holandiešu - CBG-MEB (College ter Beoordeling van Geneesmiddelen)

zentiva a.s. u. kabelovny 130 10237 prague (tsjechiË) - everolimus 2,5 mg/stuk - tablet - butylhydroxytolueen (e 321) ; crospovidon (e 1202) ; hypromellose, type 2910 (3 - 15 mpa.s) (e 464) ; lactose 0-water ; lactose 1-water ; magnesiumstearaat (e 470b) - everolimus

Nīderlande - holandiešu - CBG-MEB (College ter Beoordeling van Geneesmiddelen)

zentiva a.s. u. kabelovny 130 10237 prague (tsjechiË) - everolimus 5 mg/stuk - tablet - butylhydroxytolueen (e 321) ; crospovidon (e 1202) ; hypromellose, type 2910 (3 - 15 mpa.s) (e 464) ; lactose 0-water ; lactose 1-water ; magnesiumstearaat (e 470b) - everolimus

Eiropas Savienība - holandiešu - EMA (European Medicines Agency)

abbvie deutschland gmbh & co. kg - upadacitinib - artritis, reumatoïde - immunosuppressiva - rheumatoid arthritisrinvoq is indicated for the treatment of moderate to severe active rheumatoid arthritis in adult patients who have responded inadequately to, or who are intolerant to one or more disease-modifying anti-rheumatic drugs (dmards). rinvoq may be used as monotherapy or in combination with methotrexate. psoriatic arthritisrinvoq is indicated for the treatment of active psoriatic arthritis in adult patients who have responded inadequately to, or who are intolerant to one or more dmards. rinvoq may be used as monotherapy or in combination with methotrexate. axial spondyloarthritisnon-radiographic axial spondyloarthritis (nr-axspa)rinvoq is indicated for the treatment of active non-radiographic axial spondyloarthritis in adult patients with objective signs of inflammation as indicated by elevated c-reactive protein (crp) and/or magnetic resonance imaging (mri), who have responded inadequately to nonsteroidal anti-inflammatory drugs (nsaids). ankylosing spondylitis (as, radiographic axial spondyloarthritis)rinvoq is indicated for the treatment of active ankylosing spondylitis in adult patients who have responded inadequately to conventional therapy. atopic dermatitisrinvoq is indicated for the treatment of moderate to severe atopic dermatitis in adults and adolescents 12 years and older who are candidates for systemic therapy. ulcerative colitisrinvoq is indicated for the treatment of adult patients with moderately to severely active ulcerative colitis who have had an inadequate response, lost response or were intolerant to either conventional therapy or a biologic agent.  crohn’s diseaserinvoq is indicated for the treatment of adult patients with moderately to severely active crohn’s disease who have had an inadequate response, lost response or were intolerant to either conventional therapy or a biologic agent.